Zura Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation antibody therapies. Headquartered in Cambridge, Massachusetts, the company specializes in the design of mono- and multi-specific antibodies aimed at addressing complex disease biology in oncology, immunology and rare disorders. Zura Bio’s scientific team applies advanced protein engineering techniques to create therapeutic candidates with enhanced stability, specificity and manufacturability.
The company’s proprietary antibody platform enables rapid generation and optimization of novel multispecific formats, allowing simultaneous engagement of multiple targets or disease pathways. By fine-tuning antibody architecture, Zura Bio seeks to improve pharmacokinetic properties and reduce off-target effects compared to conventional monoclonal antibodies. This platform underpins a pipeline of preclinical programs designed to tackle immune checkpoint regulation, tumor microenvironment modulation and inflammatory signaling.
Zura Bio’s lead programs are advancing through preclinical development, with select candidates poised for IND-enabling studies. The company collaborates with academic laboratories and industry partners to validate target biology and accelerate translational efforts. Through these partnerships, Zura Bio aims to leverage external expertise while retaining full control of its proprietary engineering technologies.
Founded by a team of experienced researchers in antibody discovery and development, Zura Bio is committed to addressing unmet medical needs by delivering differentiated therapeutic solutions. The company’s long-term strategy emphasizes clinical proof-of-concept studies in areas with high barriers to treatment, with the goal of improving outcomes for patients who have limited options under current standards of care.
AI Generated. May Contain Errors.
Free ZURA Stock Alerts